Discussion
The first participant has been dosed in a proof-of-concept, open-label Phase 2a clinical trial testing Consynance Therapeutics’ experimental oral therapy CSTI-500 in adolescents and adults with Prader-Willi syndrome (PWS). Supported in part by a venture philanthropy investment from the Foundation for Prader-Willi Research (FPWR), the Phase 2a study…